PT-141 (bremelanotide) is a melanocortin receptor agonist investigated in neurogenic pathway research.
Selective activity at MC4R, central to research on arousal signaling.
Clinical research literature exists for related indications; supplied here strictly for laboratory research.
- Sexual-response and arousal research
- Melanocortin CNS-pathway studies
- Behavioural neuroscience investigation
PeriodDoseUnits (U-100)
Research protocol0.5–2 mg—
Adjust dose based on study design and tolerability. Consult your protocol.
For research use only. Not for human or veterinary consumption. Not FDA-approved for the treatment or prevention of any disease.